Drug Profile
AL 39324
Alternative Names: AL-39,324; Receptor tyrosine kinase inhibitor - NovartisLatest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Unknown
- Developer Alcon
- Class Eye disorder therapies
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic retinopathy
- Discontinued Age-related macular degeneration
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 01 Nov 2012 No development reported - Phase-I/II for Diabetic retinopathy in USA (Intravitreous)
- 08 Apr 2011 Novartis completes acquisition of Alcon